Safety and effectiveness of ultra-low temperature #cryoablation of monomorphic #ventricular #tachycardia in patients with ischemic and non-ischemic #cardiomyopathies - Cryocure-VT trial - visual summary #EHRA2024 #EHRA_ESC

Atul Verma Usha Tedrow Serge Boveda Emma Svennberg

Impact of preventive substrate #catheter #ablation on implantable #cardioverter -defibrillator interventions in pts w/ #ischaemic #cardiomyopathy & #infarct -related #coronary chronic total occlusion-PREVENTIVE VT trial-visual summary #EHRA2024 #EHRA_ESC
Serge Boveda Emma Svennberg

🔥 RELIEVE-HF: In patients with #HF , an #interatrial shunt was safe, but it did not improve symptoms or prognosis. The interatrial shunt appeared to be beneficial in patients with reduced EF, but harmful in those with preserved EF ⚡️

acc.org/latest-in-card…

#ACC24 American College of Cardiology

Check out my #editorial on oral #anticoagulants and #antiplatelet treatment in different settings

#EHJPharmacotherapy

. EHRAPresident discusses with Ruben Casado Arroyo the #EHRA_ESC Practical Guide to #Antiarrhythmic Drug Therapy during #EHRA2024 👇

#EPeeps #ablation #arrhythmia #YoungEP

'Evidence is what distinguishes a palm reader from a physician'
John Mandrola, MD brings you his insights on evidence in #electrophysiology during #EHRA2024
Interviewed by Dominik Linz 👇

#EHRA_ESC #EPeeps

Sodium-glucose cotransporter-2 inhibitors and the risk of #afib in patients with type 2 diabetes: a population-based cohort study 👇

#EHJPharmacotherapy

Use of #PPI is associated with ⬆️ risk of out-of-hospital cardiac arrest in the general population: data from a nationwide 🇩🇰 study now published in #EHJPharmacotherapy 👉 bit.ly/3Tn1HIB

Diego Segura-Rodríguez SABOURETCardiologist Felice Gragnano EHJ-CVP Editor-in-Chief #OHCA #heartattack

DAPA-MI did not show benefit of early initiation of #SGLT2i on #MACE or HHF in low-risk MI patients. Why the discordance? Read more in #EHJPharmacotherapy 👉
academic.oup.com/ehjcvp/article…

Mattia Galli Felice Gragnano DoreenTan.CVPx European Society of Cardiology Journals European Society of Cardiology

#postMI #HFhospitalisation

Rethinking cholinesterase Inhibitors, icosapent ethyl, fenofibrate and some controversial OAC data in the frail! Read all about it 👉 academic.oup.com/ehjcvp/article…

#EHJPharmacotherapy

#MACE #repurposingofdrugs #fibrates #frailAF #DOAC

🔍A journey into the pleiotropic effects of ticagrelor in this elegant study exploring the effects of ticagrelor vs clopidogrel on ischemic preconditioning assessed by intracoronary-ECG: the TAPERS randomized study🎯bit.ly/3TeszdF

#EHJPharmacotherapy Ricky Turgeon PharmD

What is the best antithrombotic regimen after #TAVR ?
This updated network meta-analysis provides the comparative effects of different treatments🖥️ academic.oup.com/ehjcvp/advance…

Ricky Turgeon PharmD Arden Barry

#EHJPharmacotherapy #TAVI #Cardiox #cardiotwitter

Net clinical benefit of #DPI with low-dose #rivaroxaban consistently observed in CAD patients at low, moderate or high CV risk: Data from the COMPASS trial in #EHJPharmacotherapy 👉 bit.ly/3TKFztf

Dr. Deepak L. Bhatt MIЯVΛƬ #IC Felice Gragnano EHJ-CVP Editor-in-Chief

Join Erik Lerkevang Grove WEBodenMD and Juan Carlos Kaski for the webinar 'What is optimal medical therapy for chronic coronary syndromes?'
It's on 26 March 18:00 to 19:00 CET and it's free 👉
esc365.escardio.org/event/1543

#ESCWebinar #ESCPharmacotherapy #CCS

#EHJPharmacotherapy best of: PATH-PCI trial. This is the largest (n=2237) RCT on guided selection of P2Y12 inhibiting therapy vs standard therapy in CCS. Guided therapy was associated w/ a 32% reduction in the net clinical benefit 180 days after PCI bit.ly/3Ix8kmD

#DAPT

Standard 12-month #DAPT is still the strategy of choice after #ACS
Should bleeding reduction strategies be the new standard of care? This #PharmaPulse explores Pros & Cons academic.oup.com/ehjcvp/advance…

Francesco Costa Eliano Navarese Mattia Galli
#EHJPharmacotherapy
#pharmacotherapy

💥Net clinical benefit of extended dual pathway inhibition according to Baseline risk in patients with chronic coronary syndrome: a COMPASS substudy academic.oup.com/ehjcvp/article…
Felice Gragnano EHJ-CVP Editor-in-Chief Nikos Pyrpyris European Society of Cardiology Journals

️‍🔥 Anticoagulation with #FXI inhibitors: an updated review of the latest evidence from RCTs and future perspectives in #EHJPharmacotherapy ⬇️

academic.oup.com/ehjcvp/advance…

Davide Capodanno EHJ-CVP Editor-in-Chief European Society of Cardiology Journals European Society of Cardiology Claudio Laudani Antonio Greco #CardioTwitter #Cardiology #AFib

On #IWD2024 I take the opportunity to share with you that Bianca Rocca Bianca has been voted Chairperson-Elect 2024-2026 for the ESC WG of Cardiovascular Pharmacotherapy #ESCPharmacotherapy

Big congratulations 👍

#InspireInclusion European Society of Cardiology

Have you read about the novel s.c. #furosemide formulation delivered by an abdominal patch infusion device in #HF ? One of the most read late-breaking science in #EHJPharmacotherapy academic.oup.com/ehjcvp/article…
Diego Segura-Rodríguez Giuseppe Galati Henry Han #heartfailure #pharmacotherapy